Interestingly, these findings could be recapitulated in other preclinical models such as in the TS/A breast cancer model and the Lewis lung carcinoma (LLC) model, where Flt3L therapy also increased the abundance of DCs in the TME (Figured S4A, B), but within the CCR7+ DC compartment, specifically increased CD81+migcDC1s (Figures S4C–F). This evidence concerns the gene CCR7 and breast cancer.